Wide Ranks

CELUW

0.0189

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 312.20 %
Current Ratio 0.26 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -264.30 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins -264.30 % Operating Margins -84.02 %
Balance Sheet
Total Cash 467000 Total Cash Per Share 0.0210 Total Debt 67 M
Total Debt To Equity 242.19 Current Ratio 0.26 Book Value Per Share 1.27
All Measures
Message Board Id finmb_408304689 Return On Equity -1.54 City Florham Park
Uuid 6086f2d4-0d51-3463-9a06-547cab6d2491 Previous Close 0.0157 Book Value 1.27
Beta 0.5090 Total Debt 67 M Volume 12863
Price To Book 0.0149 Fifty Two Week Low 0.0189 Total Cash Per Share 0.0210
Total Revenue 42 M Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -84.02 % Net Income To Common -112830000 Trailing Peg Ratio None
Total Cash 467000 Revenue Per Share 2.10 Ebitda Margins -84.11 %
Trailing PE 0.0000 Regular Market Previous Close 0.0157 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Open 0.0250 Free Cashflow -33171750
State NJ Dividend Yield 0.00 % Return On Assets -0.1463
Time Zone Short Name EST Trailing Eps -0.8700 Day Low 0.0189
Address1 170 Park Avenue Target High Price 0.0000 Price Hint 4
Website https://www.celularity.com Forward Eps 0.0000 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 20.50 % Is_sp_500 False
Regular Market Day High 0.0250 Profit Margins -264.30 % Debt To Equity 242.19
Fifty Two Week High 0.0250 Day High 0.0250 Regular Market Open 0.0250
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 312.20 %
Operating Cashflow -20514000 Currency USD Time Zone Full Name America/New_York
Is_nasdaq_100 False Market Cap 0.0000 Zip 07932
Quote Type EQUITY Industry Biotechnology Long Name Celularity Inc.
Regular Market Day Low 0.0189 Current Price 0.0189 Financial Currency USD
Current Ratio 0.26 Gross Margins 60.24 % Industry Disp Biotechnology
Country United States Float Shares 10 M Forward PE 0.0000
Regular Market Volume 12863 Ebitda -35905000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.

The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments.

Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.

Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand.

The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.

Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.